HER2-positive Gastric Cancer
Conditions
Brief summary
Investigators assessed the effectiveness of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Interventions
DRUGHLX10, Trastuzumab and Chemotherapy
HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically proven metastatic or locally advanced HER2-positive gastric cancer 2. Documented disease progression after receiving prior line of trastuzumab-containing chemotherapy for gastric cancer 3. Able and willing to give written informed consent and has signed the informed consent form (ICF), prior to performance of any trial activities. 4. Eligible male and female subjects aged ≥18 years. 5. Has measurable disease as determined by RECIST 1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 7. Has baseline left ventricular ejection fraction (LVEF) ≥ 55%. 8. Adequate organ function as demonstrated by laboratory test results within 14 days prior to first dose of study treatment. 9. Have urinary protein that is \<2 on dipstick or routine urinalysis. 10. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to first dose of study treatment. 11. Female subjects of childbearing potential and male subjects should be willing to use methods of birth control for the course of the study and up to 120 days after the last dose of study treatment.
Exclusion criteria
1. Received prior anticancer treatment with targeted agents, chemotherapy, or radiotherapy within 14 days, with monoclonal antibodies within 28 days, has previously received treatment with ramucirumab, or has participated in another clinical trial within 14 days prior to start of study treatment. 2. Has experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to treatment. 3. Has experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 3 months prior to treatment. 4. Has history of severe thromboembolism, including deep vein thrombosis and pulmonary embolism within 6 months prior to treatment. 5. Has an active or ongoing infection, symptomatic congestive heart failure, （6）uncontrolled angina pectoris, symptomatic or poorly controlled arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator. （7）Has ongoing or active psychiatric illness or social situation that would limit compliance with study requirements. （8）Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. （9）Has evidence of active, non-infectious pneumonitis. （10）Have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 4 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | 18 months after start of treatment | Progression-free survival in patients with HER2-positive gastric cancer receiving HLX10, trastuzumab, and chemotherapy combination treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | through study completion, an average of 2 years | Overall survival |
| Objective response rate according to RECIST 1.1 | through study completion, an average of 2 years | Objective response rate according to RECIST 1.1 |
| Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE | Throughout the overall study period as well as up to 3 months after the last dose study treatment for each subject | Safety and tolerability based on incidence of treatment-emergent adverse events as assessed by CTCAE |
Outcome results
None listed